<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00240461</url>
  </required_header>
  <id_info>
    <org_study_id>CVT-E002-2005-2</org_study_id>
    <nct_id>NCT00240461</nct_id>
  </id_info>
  <brief_title>Use of COLD-fX to Prevent Respiratory Infections in Community Dwelling Seniors</brief_title>
  <official_title>Efficacy and Safety of COLD-fX in the Prevention of Respiratory Infections in Community-dwelling Seniors: a Multi-center, Randomized, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Health, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Afexa Life Sciences Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>IWK Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of BC Gerontology &amp; Diabetes Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Capital Health, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Seniors are a population vulnerable to respiratory infections. It is hypothesized that
      regular use of COLD-fX following an influenza vaccination would potentially augment immune
      response in the elderly. Use of COLD-fX may also provide additional protection again
      respiratory infection and reduce the incidence and severity of respiratory infections in
      otherwise healthy seniors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible seniors will be randomly placed into three groups to receive 400 mg/day, 800mg/day
      or a placebo for a period of six months beginning in October. Daily dosing will be recorded
      as well as any symptoms not related to having a respiratory infection. For seniors who
      experience a respiratory infection, they are asked to call a study nurse who will take a
      nasopharyngeal swab. The seniors are also asked to record on a diary card the severity of
      their symptoms on a scale from 0-3 (none, mild, moderate, severe). Symptoms include cough,
      fever, runny nose, stuff nose, aches and pains, headache, chills, sneezing, ear aches and
      fatigue.The swab will be taken to the lab for testing for upper respiratory viruses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effects of COLD-fX supplementation on the incidence of laboratory and clinically confirmed upper respiratory infections.</measure>
    <time_frame>During the study time frame of 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of the treatment on the incidence and frequency of all respiratory infections meeting the Jackson criteria and to determine the efficacy of COLD-fX supplementation on the severity and duration of symptoms.</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">780</enrollment>
  <condition>Respiratory Tract Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mg COLD-fX Natural health products 2 times daily for six months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2 - 400 mg COLD FX Natural health product - 2 times daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive crystalline substance. This is the placebo arm in which subject receive 200 mg of the placebo 2 times daily for 6 months. Placebo is an inactive crystalline substance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>COLD-fX natural health product</intervention_name>
    <description>200 mg/COLD-fX natural health product - 2 capsules twice daily for 6 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Natural health product</other_name>
    <other_name>dietary supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>COLD-fX</intervention_name>
    <description>400 mg COLD-fX natural health product 2 times daily for 6 months</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>naural health products</other_name>
    <other_name>dietary supplements</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>crystalline substance 200 mg twice daily for 6 months</description>
    <arm_group_label>3</arm_group_label>
    <other_name>none available</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 65 years of age and older

          -  current season influenza immunization

          -  available for follow-up visits

          -  willing and able to sign written informed consent

        Exclusion Criteria:

          -  HIV infection

          -  malignancy (under active observation or treatment)

          -  unstable cardiovascular diseases

          -  renal abnormalities (serum creatine &gt;200umol/l)

          -  pulmonary disease (chronic bronchitis, emphysema, or asthma requiring treatment in the
             last 3 months with oral steroids - prednisone &gt;10mg/day, other chronic respiratory
             illness)

          -  acute or active chronic liver disease

          -  neurologic or psychiatric disease (progressive or currently under treatment

          -  active tuberculosis

          -  multiple sclerosis

          -  bleeding disorders

          -  planned surgery over the course of the trial

          -  on immunosuppressive therapy

          -  taking oral steroids at dose = to prednisone 10 mg/day or more

          -  taking phenelzine, pentobarbital, haloperidol, warfarin, heparin

          -  use of natural health products(except the study product and vitamins and minerals with
             a dose &lt;600 mg/day of vitamin E and containing no vitamin K) including echinacea or
             ginseng-containing products (tea, capsules, extracts, tablets)

          -  current alcohol/drug abuse

          -  major surgery in the past 6 months

          -  allergies to ginseng
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerry Predy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capital Health, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shelly McNeil MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IWK Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan McElhaney</last_name>
    <role>Principal Investigator</role>
    <affiliation>UBC Gerontology and Diabetes Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Simor MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert Osterhaus Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alberta Health Services</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5M 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UBC Gerontology and Diabetes Research</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Albert Osterhaus</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2005</study_first_submitted>
  <study_first_submitted_qc>October 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2005</study_first_posted>
  <last_update_submitted>July 6, 2011</last_update_submitted>
  <last_update_submitted_qc>July 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Gerry Predy</name_title>
    <organization>Capital Health</organization>
  </responsible_party>
  <keyword>respiratory</keyword>
  <keyword>infection</keyword>
  <keyword>influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

